Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
CONMED Corporation (NYSE: CNMD) is a medical equipment company in the surgical and medical instrument manufacturing industry. Its products are used in sports medicine procedures and general surgeries across specialties such as orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. The CONMED news feed on this page aggregates company-issued press releases and other coverage related to its operations, strategy and financial performance.
Recent news highlights include updates on portfolio optimization, such as CONMED’s announced intent to exit its gastroenterology product lines and to conclude a distribution agreement for a biliary stent product. The company has linked this decision to a focus on core markets in minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair. News items also cover quarterly and year-to-date financial results, where CONMED reports net sales by orthopedic and general surgery categories, and by single-use and capital products, along with domestic and international growth metrics.
Investors and observers can also follow governance and leadership developments through this news stream. CONMED has issued releases about changes to its Board of Directors, including the appointment of a new independent director and the resignation of another director to take a leadership role at another organization. The company has also announced a planned transition of its Chief Financial Officer, describing the timing and advisory period associated with that change.
Other news topics include capital allocation decisions, such as the declaration of a quarterly cash dividend and the subsequent authorization of a share repurchase program with suspension of the dividend, as well as participation in healthcare investment conferences where CONMED presents investor materials and financial guidance. Users interested in CNMD can use this page to review these types of announcements over time and to see how the company describes its strategy, operations and financial outlook.
CONMED (NYSE: CNMD) reported its Q2 2024 financial results, showing sales of $332.1 million, a 4.5% year-over-year increase (5.2% in constant currency). Domestic revenue rose 6.1%, while international revenue grew 2.6% (4.0% in constant currency). The company's diluted net earnings per share (GAAP) reached $0.96, up from $0.43 in Q2 2023. Adjusted diluted net earnings per share increased by 18.1% to $0.98.
However, CONMED revised its 2024 outlook due to ongoing supply chain challenges. The company now expects full-year revenue between $1.305 billion and $1.315 billion, down from the previous range of $1.330-$1.355 billion. The adjusted diluted net earnings per share forecast was lowered to $3.95-$4.02, from the prior range of $4.25-$4.35.
CONMED (NYSE: CNMD) is set to release its financial results for the second quarter of 2024 on July 31, 2024, after the market close. A conference call to discuss these results will be hosted by the company's management at 4:30 p.m. ET on the same day. Investors can participate in the conference call by pre-registering to obtain the dial-in number and passcode. The call will also be webcast live on the 'Investors' section of CONMED's website, with a replay available approximately one hour after the call ends.
CONMED (NYSE: CNMD) announced that Curt R. Hartman, Chair of the Board, President, and CEO, along with Todd W. Garner, Executive VP and CFO, will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for 8:00 a.m. ET on June 6, 2024.
A live webcast will be accessible via the company's website and will be available for replay following the event.
CONMED (NYSE: CNMD) has announced a quarterly cash dividend of $0.20 per share. The announcement was made on May 22, 2024, and the dividend will be payable on July 5, 2024. Shareholders of record as of June 14, 2024, will be eligible to receive this dividend. This decision reflects the company's ongoing commitment to returning value to its shareholders.
CONMED (NYSE: CNMD) will be presenting at the BofA Securities Healthcare Conference with top executives discussing the company's future on May 14, 2024. The event will be live-streamed on the company's website for investors to access.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.